ImmunoGen Stock Jumps 140% After Positive Drug Trial Data

ImmunoGen’s shares soared 136% on Wednesday after the biotech company reported “significant and clinically meaningful” survival results in a phase 3 trial of its Elahere treatment among patients with ovarian cancer. The trial found that the drug reduced the risk of death by 33% among patients with…#immunogen #imgn #annaberkenblit #elahere
Source: Reuters: Health - Category: Consumer Health News Source Type: news